---
schema_version: "secwatch.filing_event.v1"
accession: "0001944048-26-000141"
form_type: "8-K"
ticker: "KVUE"
cik: "0001944048"
company_name: "Kenvue Inc."
filed_at: "2026-08-06T10:48:04+00:00"
generated_at: "2026-08-06T10:50:08.152555+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Kenvue Q2 net sales +3.0%, adj. EPS $0.31 (+7% YoY); reaffirms Q4 Kimberly-Clark deal close

## Summary
- Net sales $3.0B, +3.0% YoY; organic sales +1.6% driven by value realization +0.9% and volume +0.7%.
- Diluted EPS $0.24 (+9% YoY); adjusted diluted EPS $0.31 (+7% YoY); adjusted gross margin 60.2%.
- Skin Health & Beauty led with +5.1% net sales; Self Care +2.2%, Essential Health +2.3%.
- FDA approved Tylenol with Naproxen (first OTC fixed-dose combo); 3-year exclusivity, launching soon.
- Pending Kimberly-Clark acquisition on track for Q4 2026; no forward guidance provided.

## SEC filing metadata
- accession: 0001944048-26-000141
- form_type: 8-K
- ticker: KVUE
- cik: 0001944048
- company_name: Kenvue Inc.
- filed_at: 2026-08-06T10:48:04+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1944048/000194404826000141/0001944048-26-000141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1944048/000194404826000141/kvue-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001944048-26-000141
- JSON: https://secwatch.observer/filing/0001944048-26-000141.json
- Plain text: https://secwatch.observer/filing/0001944048-26-000141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.